July/August 2010

TABLE OF CONTENTS

Prefilled Syringes: Injecting the End-User’s Perspective

Frost & Sullivan Analyst Misty Hughes reports that injectable drugs and prefilled syringes have and will continue to play an integral role in the future of the pharmaceutical and biotechnology markets.

 

Transdermal Delivery – Making a Comeback!

Contributor Cindy H. Dubin learns from some leading transdermal delivery companies that while there will always  be a need for passive-based systems, active technology is enabling delivery of hard-to-deliver products.

 

Optimizing Cascade Impactor Testing for Characterizing Orally Inhaled & Nasal Drug Products

Mark Copley reviews the significance of cascade impaction as a core analytical technique and the challenge to individual laboratories to ensure it is used to optimum effect to achieve maximum accuracy and productivity.

 

Pulmonary Drug Delivery: Going Beyond Lung Diseases

Frost & Sullivan Analyst Katheryn Symank, MS, believes with advancing technology and new innovations, the true potential of pulmonary drug delivery is only now being appreciated.

 

Creating Safer Pain Relievers Using Proton Pump Inhibitor Drug Delivery Mechanisms

John Fort, MD, explains how POZEN’s investigational PA franchise, a combination of aspirin and omeprazole, is intended to deliver the cardiovascular benefits of aspirin with a lower incidence of gastric ulcers than EC aspirin.

 

The Power of the Endothelium: Novel Delivery Approaches to Promoting Vascular Healing

Helen Nugent, PhD, suggests targeted local therapy with tissue-engineered endothelial cells to be a novel therapeutic approach that is safe and ideally suited to control the response to injury, promote healing, and inhibit clinical vascular dysfunction.

 

Trends in Ophthalmic Preservatives: A Review

Megha Barot, MPharm; Mitan R. Gokulgandhi, MPharm; and Jolly R. Parikh, PhD; compare and review the most common preservatives in ophthalmic preparations for glaucoma and surface eye disease – benzalkonium chloride, chlorobutanol, sodium perborate, and stabilized oxychloro complex.

 

An Industrial Insight Into Pellet Manufacture by Extrusion Spheronization

E.L. McConnell, PhD; S.R. Pygall, PhD; R. Ward, PhD; and C. Seiler, PhD; review the production of pellets by extrusion-spheronization, addressing some of the major processing considerations and challenges and offering potential methods of resolution.

 

Cambrex Corporation: Accelerating Development & Commercialization

Drug Delivery Executive: Dan Giambattisto, VP of Drug Delivery at Cambrex, discusses how his company continues to provide and enhance its drug delivery technologies for pharmaceutical preparations.

 

Particle Sciences: Providing Formulation & Analytical Services to Meet Demanding Drug Delivery Challenges

Drug Delivery Executive: Dr. Robert W. Lee, VP of Drug Development for Particle Sciences, talks about thriving in today’s tough business environment.

 

A Path to Orally Active RNAi Therapeutics

Joanne Kamens, PhD; Pamela Pavco, PhD; and Anastasia Khvorova, PhD; describe in this report a first proof-of-concept study demonstrating siRNA delivery to phagocytic cells through oral administration.

 

Intezyne: Targeting Delivery of Chemotherapeutics

Executive Summary: Habib Skaff, PhD, CEO of Intezyne speaks about his expectations for IVECT and how his company must keep its focus in oncology to be successful.

 

DEPARTMENTS

 

Market News & Trends

 

Technology Showcase

 

External Delivery

Who’s in Charge Here?

 

 

COVER

FEATURES